my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Abstract
Cross‐neutralisation has been demonstrated for haemorrhagic venoms including Echis spp. and Cerastes spp. and for Australia elapid procoagulant toxins. A previous study showed that commercial tiger snake antivenom (TSAV) was able to neutralise the systemic effects of the Egyptian cobra, N. haje, in vivo but it is unclear if this was true cross‐neutralisation. The aim of the current study was to determine if TSAV can neutralise the in vitro neurotoxic effects of N. haje venom. Both N. scutatus (10 μg/ml) and N. haje (10 μg/ml) venoms caused inhibition of indirect (supramaximal V, 0.1 Hz, 0.2 ms) twitches of the chick biventer cervicis nerve‐muscle preparation with t90 values (i.e. the time to produce 90% inhibition of the original twitch height) of 26 ± 1 min. (n=4) and 36 ± 4 min.; (n=4). This effect at 10 μg/ml was significantly attenuated by the prior addition of TSAV (5 U/ml). A comparison of the reverse‐phase HPLC profiles of both venoms showed some similarities with peak elution times, and SDS‐Page analysis elucidated comparable bands across both venoms. Further analysis using western immunoblotting indicated TSAV was able to detect N. haje venom, and enzyme immunoassay showed that in‐house biotinylated polyclonal monovalent N. scutatus antibodies were able to detect N. haje venom. These findings demonstrate cross‐neutralisation between different and geographically separated snakes supporting potential immunological similarities in snake toxin groups for a large range of snakes. This provides more evidence that antivenoms could be developed against specific toxin groups to cover a large range of snakes.
| Authors: | Rachelle Kornhauser, Geoffrey K. Isbister, Margaret A. O'Leary, Peter Mirtschin, Nathan Dunstan, Wayne C. Hodgson | |
| Journal: | Basic & Clinical Pharmacology & Toxicology | |
| Year: | 2012 | |
| Pages: | n/a | |
| DOI: | 10.1111/j.1742-7843.2012.00925.x | |
| Publication date: | 12-07-2012 |
Watchlist
This is where you can add this publication to your personal favourites.
Additional Information
Cancer risks for MLH1 and MSH2 mutation carriers
ABSTRACT We studied 17,576 members of 166 MLH1 and 224 MSH2 mutation‐carrying families from the Colon Cancer Family Registry. Average cumulative risks of colorectal cancer (CRC), endometrial cancer (EC) and other cancers for carriers were estimated using modified segregation analysis co ... more
Scope Flavonoids have well‐known antioxidant, anti‐inflammatory, and anti‐cancer activities. Isoflavone genistein is considered a potent antioxidant agent against oxidative stress. Although several mechanisms have been proposed, a clear antioxidant mechanism of genistein is still remain ... more
Abstract People can get oral cancers from UV (290‐400 nm) exposures. Besides high outdoor UV exposures, high indoor UV exposures to oral tissues can occur when consumers use UV‐emitting tanning devices to either tan or whiten their teeth. We compared the carcinogenic risks of skin to or ... more
Marijuana use may increase risk of testicular cancer
A new study from the University of Southern California (USC) has found a link between recreational marijuana use and an increased risk of developing subtypes of testicular cancer that tend to carry a somewhat worse prognosis. Published in CANCER the findings suggest that the potential cance ... more
New Study into Bladder Regeneration Heralds Organ Replacement Treatment
Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient’s own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also ... more
Stem Cells journal awards human cord-blood research
The journal Stem Cells has announced Dr. Cinzia Rota as the winner of the annual Stem Cells Young Investigator Award. Co-sponsored by the International Stem Cell Symposium, the $10,000 prize is annually given to a young scientist who is the principal author of a research paper published in ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
